Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 10/2005

01-07-2005 | Review Article

Pharmacotherapy for Obesity

Authors: Dr Lisa L. Ioannides-Demos, Joseph Proietto, John J. McNeil

Published in: Drugs | Issue 10/2005

Login to get access

Abstract

Pharmacotherapy for the management of obesity is primarily aimed at weight loss, weight loss maintenance and risk reduction, and has included thyroid hormone, amphetamines, phentermine, amfepramone (diethylpropion), phenylpropanolamine, mazindol, fenfluramines and, more recently, sibutramine and orlistat. These agents decrease appetite, reduce absorption of fat or increase energy expenditure.
Primary endpoints used to evaluate anti-obesity drugs most frequently include mean weight loss, percentage weight loss and proportion of patients losing ≥5% and ≥10% of initial body weight. Secondary endpoints may include reduction in body fat, risk factors for cardiovascular disease and the incidences of diseases such as diabetes mellitus.
Most pharmacotherapies have demonstrated significantly greater weight loss in patients on active treatment than those receiving placebo in short-term (≤1 year) randomised controlled trials of pharmacological treatment in conjunction with a calorie-controlled diet or lifestyle intervention. The evidence of long-term efficacy is limited to sibutramine (2 years) and orlistat (4 years). These are the only drugs currently approved for the long-term management of obesity in adults. Sibutramine recipients randomised following 6 months’ treatment to either sibutramine or placebo demonstrated significantly better weight maintenance at 2 years than those taking placebo (p < 0.001), with ≥10% loss of initial bodyweight in 46% of patients. For patients taking orlistat, weight loss was 2.2kg greater than those on placebo at 4 years (p < 0.001), with significantly more patients achieving ≥10% loss of initial bodyweight (26.2% and 15.6%, respectively; p < 0.001).
Other drugs that have been evaluated for weight loss include ephedrine, the antidepressants fluoxetine and bupropion, and the antiepileptics topiramate and zonisamide. Two clinical trials with fluoxetine both reported no significant difference in weight loss compared with placebo at 52 weeks. Clinical trials evaluating ephedrine, bupropion, topiramate and zonisamide have demonstrated significantly greater weight loss than placebo but have been limited to 16–26 weeks’ treatment.
A major obstacle to the evaluation of the clinical trials is the potential bias resulting from low study completion rates. Completion rates varied from 52.8% of phentermine recipients in a 9-month study, to 40% of fenfluramine recipients in a 24-week comparative study with phentermine and 18% of amfepramone recipients in a 24-week study. One-year completion rates range from 51% to 73% for sibutramine and from 66% to 85% for orlistat. Other potential sources of bias include run-in periods and subsequent patient selection based on compliance or initial weight loss.
Several potential new therapies targeting weight loss and obesity through the CNS pathways or peripheral adiposity signals are in early phase clinical trials. Over the next decade the drug treatment of obesity is likely to change significantly because of the availability of new pharmacotherapies to regulate eating behaviours, nutrient partitioning and/or energy expenditure.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Farrigan C, Pang K. Obesity market overview. Nat Rev Drug Discov 2002; 1: 257–8PubMed
2.
Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Saf 1999; 20: 119–31PubMed
3.
Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001; 161: 1814–24PubMed
4.
Haddock CK, Poston WSC, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes 2002; 26: 262–73
5.
Haiford JC. Clinical pharmacotherapy for obesity: current drugs and those in development. Curr Drug Targets 2004; 5: 637–46
6.
National Institutes of Health, National Heart, Lung, and Blood Institute, North American Association for the Study of Obesity. The practical guide: identification, evaluation and treatment of overweight and obesity in adults. NIH Publication No. 00-4084, October 2000 [online]. Available from URL: http://​www.​nhlbi.​nih.​gov/​guidelines/​obesity/​prctgd_​b.​pdf [Accessed 2005 May 24]
7.
8.
9.
National Institutes of Health, National Heart, Lung, and Blood Institute, in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH Publication No. 98-4083. Washington, DC: US Government Press, 1998 Sep [online]. Available from URL: http://​www.​nhlbi.​nih.​gov [Accessed 2005 May 24]
10.
11.
Weintraub M. Long-term weight control: the National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992; 51 Suppl.: 581–646PubMed
12.
Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 2002; 166: 1307–8PubMed
13.
Bray GA. A concise review on the therapeutics of obesity. Nutrition 2000; 16: 953–60PubMed
14.
Clapham JC, Arch JRS, Tadayyon M. Anti-obesity drugs: a critical review of current therapies and future opportunities. Pharmacol Ther 2001; 89: 81–121PubMed
15.
Cerulli J, Malone M. Outcomes of pharmacological and surgical treatment for obesity. Pharmacoeconomics 1998; 14: 269–83PubMed
16.
Blundell JE, Lawton CL, Haiford JCG. Serotonin, eating behaviour and fat intake. Obes Res 1995; 3 Suppl. 3: 471–6
17.
Wurtman JJ, Wurtman RJ, Reynolds S, et al. Fenfluramine suppresses snack intake among carbohydrate cravers but not among non-carbohydrate cravers. Int J Eat Disord 1987; 6: 687–99
18.
Maher TJ, Ulus IH, Wurtman RJ. Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramine [letter]. Lancet 1999; 353(9146): 38PubMed
19.
Seiler KU, Tamm G, Wassermann O. On the role of serotonin in the pathogenesis of pulmonary hypertension induced by anorectic drugs, an experimental study in the isolated, perfused rat lung. Clin Exp Pharmacol Physiol 1974; 1: 463–71
20.
Munro JF, MacCuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968; 1: 352–4PubMed
21.
Truant AP, Olon LP, Cobb S. Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study. Curr Ther Res Clin Exp 1972; 14: 726–38PubMed
22.
Weintraub M, Hasday JD, Mushlin AI, et al. A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med 1984; 144: 1143–8PubMed
23.
McKay RH. Long-term use of diethylpropion in obesity. Curr Med Res Opin 1973; 1: 489–93PubMed
24.
DeRamos EC. The use of diethylpropion in the treatment of obesity. Br J Clin Pract 1964; 18: 210–1PubMed
25.
Silverstone JT, Solomon T. The long-term management of obesity in general practice. Br J Clin Pract 1965; 19: 395–8PubMed
26.
Le Riche WH, Csima A. A long-acting appetite suppressant drug studied for 24 weeks in both continuous and sequential administration. CMAJ 1967; 97: 1016–20
27.
Greenway FL. Clinical studies with phenylpropanolamine: a metaanalysis. Am J Clin Nutr 1992; 55 (1 Suppl.): 203–5
28.
Weintraub M, Ginsberg G, Stein EC, et al. Phenylpropanolamine OROS (Acutrim) vs placebo in combination with calorie restriction and physician-managed behavior modification. Clin Pharmacol Ther 1986; 39: 501–9PubMed
29.
Greenway F, Herber D, Raum W, et al. Double-blind randomized placebo-controlled clinical trials with non-prescription medications in the treatment of obesity. Obes Res 1999; 7: 370–8PubMed
30.
Enzi G, Baritussio A, Marchiori E, et al. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity. J Int Med Res 1976; 4: 305–19PubMed
31.
Inoue S. Clinical studies with mazindol. Obes Res 1995; 3 Suppl. 4: 549–52
32.
Onishi T, Mazindol Research Group. Clinical evaluation of mazindol, an anorexiant on obesity [abstract]. Int J Obes 1990; 14: 34
33.
Vernace BJ. Controlled comparative investigation of mazindol, D-amphetamine and placebo. Obesity Bariatric Med 1974; 3: 124–9
34.
Allen GS. A double-blind clinical trial of diethylpropion hydrochloride, mazindol, and placebo in the treatment of exogenous obesity. Curr Ther Res 1977; 22: 678–85
35.
Davis R, Faulds D. Dexfenfluramine: an updated review of its therapeutic use in the management of obesity. Drugs 1996; 52(2): 696–724PubMed
36.
Guy-Grand B, Apfelbaum M, Crepaldi G, et al. International trial of long-term dexfenfluramine in obesity. Lancet 1989; II: 1142–5
37.
Mathus-Vliegen EM, van de Voorde K, Kok AM, et al. Dexfenfluramine in the treatment of severe obesity: a placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour. J Intern Med 1992; 232: 119–27PubMed
38.
Carvajal A, Garcia del Pozo J, Martin de Diego I, et al. Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis. Methods Find Exp Clin Pharmacol 2000; 22: 285–90PubMed
39.
Jones SP, Smith IG, Kelly F, et al. Long term weight loss with sibutramine [abstract]. Int J Obes Relat Metab Disord 1995; 19 Suppl. 2: 41
40.
McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African-American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicentre trial. Arch Intern Med 2000; 160: 2185–91PubMed
41.
Lean MEJ. Sibutramine: a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21 Suppl. 1: S30–6PubMed
42.
Smith IG, Jones SP, Heath MJ, et al. Categorical outcome analysis of weight loss in long-term sibutramine [abstract]. Int J Obes Relat Metab Disord 1996; 20: 157
43.
Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999; 7: 189–98PubMed
44.
Smith IG, Goulder MA. Randomised placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001; 50: 505–12PubMed
45.
McMahon FG, Weinstein SP, Rowe E, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16: 5–11PubMed
46.
James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000; 356: 2119–25PubMed
47.
Apfelbaum M, Vague P, Ziegler O, et al. Long-term maintenance of weight loss after very-low-calorie diet: efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179–84PubMed
48.
Bray GA, Ryan DH, Gordon D, et al. A double blind randomized placebo-controlled trial of sibutramine. Obes Res 1996; 4: 263–70PubMed
49.
Fanghanel G, Cortinas L, Sanchez-Reyses L, et al. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes 2000; 24: 150–5
50.
Cuellar GEM, Ruiz AM, Monsalve MC, et al. Six-month treatment of obesity with sibutramine 15mg: a double-blind, placebo-controlled monocentre clinical trial in a Hispanic population. Obes Res 2000; 8: 71–82PubMed
51.
Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286: 1331–9PubMed
52.
Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004; 164: 994–1003PubMed
53.
Arterburn D, Noël PH. Obesity: extracts from clinical evidence. BMJ 2001; 321: 1406–9
54.
McTigue KM, Harris R, Hemphill B, et al. Screening and interventions for obesity in adults: summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2003; 139: 933–49PubMed
55.
Padwal R, Li SK. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003; 27: 1437–46PubMed
56.
Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight: Cochrane Metabolic and Endocrine Disorders Group. Cochrane Database Syst Rev 2005; (2): CD004094
57.
Wadden TA, Berkowitz RI, Sarwer DB, et al. Benefits of lifestyle modification in the pharmacologic treatment of obesity. Arch Intern Med 2001; 161: 218–27PubMed
58.
Hauner H, Meier M, Jockel KH, et al. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 2003; 13: 453–9PubMed
59.
Berkowitz RI, Wadden TA, Tershakovec AM, et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003; 289(14): 1805–12PubMed
60.
Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomised double-blind controlled study. J Clin Endocrinol Metab 2005; 90: 1460–5PubMed
61.
Hanotin C, Thomas F, Jones SP, et al. A comparison of sibutramine and dexfenfluramine in the treatment of obesity. Obes Res 1998; 6: 285–91PubMed
62.
Wadden TA, Berkowitz RI, Womble LG, et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 6: 431–7
63.
Aydin N, Topsever P, Kaya A, et al. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? Tohoku J Exp Med 2004; 202: 173–80PubMed
64.
McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998; 56(6): 1093–124PubMed
65.
Heine RJ. Drug therapy for management of obesity [letter]. Lancet 2001; 357: 1287PubMed
66.
Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000; 94: 152–8PubMed
67.
Scholze J. Sibutramine in clinical practice: a PMS-study with positive effects on blood pressure and metabolic parameters. Dtsche Med Wochenschr 2002; 127: 606–10
68.
Kim SH, Lee YM, Jee SH, et al. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116–23PubMed
69.
Zannad F, Gille B, Grentzinger A, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002; 144: 508–15PubMed
70.
Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003; 26: 1027–48PubMed
71.
Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000; 9: 160–7PubMed
72.
Sjöström L, Rissanen A, Anderson T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group. Lancet 1998; 352: 167–73PubMed
73.
Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160(9): 1321–6PubMed
74.
Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity: European Orlistat Obesity Study Group. Obes Res 2000; 8: 49–61PubMed
75.
Torgerson JA, Hauptman J, Boldrin MN, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study. Diabetes Care 2004; 27: 155–61PubMed
76.
Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998; 21: 1288–94PubMed
77.
Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235–42PubMed
78.
Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999; 69: 1108–16PubMed
79.
Lindgarde F, on behalf of Orlistat Swedish Multimorbidity Study. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000; 248: 245–54PubMed
80.
Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000; 24: 306–13PubMed
81.
Reaven G, Segal K, Hauptman J, et al. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001; 87: 827–31PubMed
82.
Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: the UK Multimorbidity Study. The UK Multimorbidity Study Group. Int J Clin Pract 2002; 56: 494–9
83.
O’Meara S, Riemsma R, Shirran L, et al. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004; 5: 51–68PubMed
84.
Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532–46PubMed
85.
Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004; 80: 1461–8PubMed
86.
Leung WY, Neil TG, Chan JC, et al. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 2003; 25: 58–80PubMed
87.
Norgren S, Danielsson P, Jurold R, et al. Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr 2003; 92: 666–70PubMed
88.
McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002; 10: 642–50PubMed
89.
Ozkan B, Bereket A, Turan S, et al. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004; 163: 738–41PubMed
90.
91.
92.
Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002; 4(1): 49–55PubMed
93.
Derosa G, Mugellini A, Ciccarelli L, et al. Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolaemia: a randomized open label trial. Curr Ther Res 2002; 63: 621–33
94.
Derosa G, Mugellini A, Ciccarelli L, et al. Randomised double-blind placebo-controlled comparison of the action of orlistat, fluvastatin or both on anthropometric measurements blood pressure and lipid profile in obese patients with hypercholesterolemia prescribed a standard diet. Clin Ther 2003; 25: 1107–22PubMed
95.
James WPT, Avenell A, Broom J, et al. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes 1997; 21 Suppl. 3: 24–30
96.
Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996; 36: 647–53PubMed
97.
Levine LR, Enas GG, Thompson WL, et al. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study. Int J Obes Relat Metab Disord 1989; 13: 635–45
98.
Bray GA. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 1993; 119: 707–13PubMed
99.
Goldstein DJ, Rampey AH, Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994; 18: 129–35PubMed
100.
Darga LL, Carroll-Michals L, Botsford SJ, et al. Fluoxetine’s effect on weight loss in obese subjects. Am J Clin Nutr 1991; 54: 321–5PubMed
101.
Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002; 10: 633–41PubMed
102.
Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002; 10: 1049–56PubMed
103.
Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722–33PubMed
104.
Wilding J, Van Gaal L, Rissanen A, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects: the OBES-002 Study Group. Int J Obes 2004; 28: 1399–410
105.
Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12: 1658–69PubMed
106.
Gadde KM, Franciscy DM, Wagner II HR, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289: 1820–5PubMed
107.
Pedrinola F, Sztejnsznajd C, Lima N, et al. The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. Obes Res 1996; 4: 549–54PubMed
108.
Dhurandhar NV, Atkinson RL. Comparison of serotonin agonists in combination with phentermine for treatment of obesity [abstract]. FASEB J 1996; 10: A561
109.
Anchors M. Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity [letter]. Arch Intern Med 1997; 157: 1270PubMed
110.
Griffen L, Anchors M. The “Phen-Pro” diet drug combination is not associated with valvular heart disease. Arch Intern Med 1998; 158: 1278–9PubMed
111.
Gadde KM, Krishnan KRK, Logue EJ, et al. Bupropion SR shows promise as an effective obesity treatment [abstract]. Obes Res 1997; 5 Suppl. 1: 51
112.
Croft H, Houser T, Leadbetter R, et al. Effect of bupropion SR on weight in the long-term treatment of depression [abstract]. Obes Res 2000; 8 Suppl. 1: 10
113.
Gadde KM, Parker CB, Maner LG, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001; 9: 544–51PubMed
114.
Malchow-Moller A, Larsen S, Hey H, et al. Ephedrine as an anorectic: the story of the ‘Elsinore pill’. Int J Obes 1981; 5: 183–7PubMed
115.
Liu YL, Toubro S, Astrup A, et al. Contribution of β3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes 1995; 19: 678–85
116.
Stock MJ. Potential for β3-adrenoceptor agonists in the treatment of obesity. Int J Obes 1996; 20 Suppl. 4: 4–5
117.
Astrup AV, Breum L, Toubro S, et al. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial. Int J Obes Relat Metab Disord 1992; 16: 269–77PubMed
118.
Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev 2001; 2: 199–211PubMed
119.
Toubro S, Astrup A, Breum L, et al. The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans. Int J Obes Relat Metab Disord 1993; 17 Suppl. 3: S73–7, S82PubMed
120.
Breum L, Pedersen JK, Ahlstrom F, et al. Comparison of an ephedrine/caffeine combination and dexfenfluramine in treatment of obesity: a double-blind multi-centre trial in general practice. Int J Obes Relat Metab Disord 1994; 18: 99–103PubMed
121.
Molnar D, Torok K, Erhardt E, et al. Safety and efficacy of treatment with an ephedrine/caffeine mixture: the first double-blind placebo-controlled pilot study in adolescents. Int J Obes Relat Metab Disord 2000; 24: 1573–8PubMed
122.
Boozer CN, Daly PA, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes Relat Metab Disord 2002; 26: 593–604PubMed
123.
Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance. JAMA 2003; 289: 1537–45PubMed
124.
Bays H, Dujovne C. Pharmacotherapy of obesity: currently marketed and upcoming agents. Am J Cardiovasc Drugs 2002; 2: 245–53PubMed
125.
Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12: 1197–211PubMed
126.
Larsen TM, Toubro S, van Baak MA, et al. Effect of a 28-d treatment with L-796568, a novel beta(3)-adrenergic receptor agonist, on energy expenditure and body composition in obese men. Am J Clin Nutr 2002; 76: 780–8PubMed
127.
Hu B, Jennings LL. Orally bioavailable β3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes. Prog Med Chem 2003; 41: 167–94PubMed
128.
Nisoli E, Tonello C, Carruba MO. Beta3-adrenergic receptors: really relevant targets for anti-obesity drugs? Curr Med Chem Central Nervous System Agents 2003; 3: 257–73
129.
Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349: 941–8PubMed
130.
Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88: 4696–701PubMed
131.
Wilding J. AOD-9604 metabolic. Curr Opin Investig Drugs 2004; 5: 436–40PubMed
132.
133.
Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology 2001; 142: 5182–9PubMed
134.
Habeck M. A succulent cure to end obesity. Drug Discov Today 2002; 7: 280–1PubMed
135.
Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292–5PubMed
136.
Proietto J, Thorburn AW. The therapeutic potential of leptin. Expert Opin Investig Drugs 2003; 12: 373–8PubMed
137.
Bell-Anderson KS, Bryson JM. Leptin as a potential treatment for obesity. Treat Endocrinol 2004; 3: 11–8PubMed
138.
Heymsfield SB, Greenberg AS, Fuujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized controlled dose escalation trial. JAMA 1999; 282: 1568–75PubMed
139.
Ettinger MP, Littlejohn TW, Schwartz SL, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized dose-ranging study. JAMA 2003; 289: 1826–32PubMed
140.
Van Gaal LF, Rissanen AM, Scheen AJ, et al., for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–97PubMed
141.
Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003; 11: 556–62PubMed
142.
Oommen KJ. Zonisamide: a new antiepileptic drug. Clin Neuropharmacol 1999; 22: 192–200PubMed
143.
Hadjikoutis S, Pickersgill TP, Smith PEM. Drug points: weight loss associated with levetiracetam. BMJ 2003; 327: 905PubMed
144.
Gidal BE, Sheth RD, Magnus L, et al. Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Res 2003; 56: 121–6PubMed
145.
Houri M, Pratley RE. Rimonabant: a novel treatment for obesity and the metabolic syndrome. Curr Diab Rep 2005; 5: 43–4
146.
147.
Results from RIO-North America trial show that first year improvements in cardiovascular risk factors maintained in the second year of treatment. American Society of Cardiology Congress, 2004 Nov 9 [online]. Available from URL: http://​www.​sanofi-synthelabo.​us/​index.​html [Accessed 2005 Feb10]
148.
Norris SL, Zhan X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004; 164: 1395–404PubMed
149.
US Preventive Services Task Force. Screening for obesity in adults: recommendations and rationale. Ann Intern Med 2003; 139: 930–2
150.
Wirth A. Reduction of body weight and co-morbidities by orlistat: the XXL-Primary Health Care Trial. Diabetes Obes Metab 2005; 7: 21–7PubMed
151.
Muls E, Kolanowski J, Scheen A, et al. The effects of orlistaton weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo controlled, multicentre study. The ObelHyx Study Group. Int J Obes 2001; 25: 1713–21
152.
Kiortsis DN, Filippatos TD, Elisat MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005; 31: 15–22PubMed
153.
Swinburn BA, Carey D, Hills AP, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab 2005; 7: 254–62PubMed
154.
Vettor R, Pagano C, Serra R, et al. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis. Diabetes Care 2005; 28: 942–9PubMed
155.
Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs 2004; 64(24): 2845–64PubMed
156.
Gupta S. Fat pill for teens: xenical may have the FDA’s blessing, but is it a good idea? Time 2003 Dec 29-2004 Jan 5; 162(26): 162PubMed
Metadata
Title
Pharmacotherapy for Obesity
Authors
Dr Lisa L. Ioannides-Demos
Joseph Proietto
John J. McNeil
Publication date
01-07-2005
Publisher
Springer International Publishing
Published in
Drugs / Issue 10/2005
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200565100-00006

Other articles of this Issue 10/2005

Drugs 10/2005 Go to the issue

Leading Article

Tigecycline

Review Article

Lansoprazole Oro-Dispersible Tablet

Correspondence

Gliclazide Modified Release

Adis Drug Evaluation

Emtricitabine

Commentary

Enoxaparin versus Heparin

Therapy in Practice

Drug Treatment of Pulmonary Arterial Hypertension